Article 20 Pharmacovigilance Procedures for Centrally Authorised Medicines

Overall structure

This article explains the Article 20 pharmacovigilance procedure under Regulation (EC) No 726/2004. It focuses specifically on the pharmacovigilance pathway for medicinal products authorised through the centralised procedure.

The article follows the procedure from the regulatory trigger through scientific assessment and decision-making to implementation and continuing pharmacovigilance.

1. What an Article 20 pharmacovigilance procedure is
2. The legal foundation in Regulation (EC) No 726/2004
3. Why the procedure is limited to centrally authorised medicines
4. When an Article 20 pharmacovigilance procedure applies
5. Who can initiate the procedure
6. The important distinction between Article 20, Article 31 and Article 107i
7. What happens when urgent national action is required
8. How the European Commission initiates the procedure
9. How PRAC and CHMP divide the scientific and regulatory work
10. The role of the MAH
11. The evidence package and questions
12. Product information, RMP and pharmacovigilance consequences
13. Commission decision and implementation
14. Practical QPPV oversight
15. References and regulatory note

1. What Is an Article 20 Pharmacovigilance Procedure?

An Article 20 pharmacovigilance procedure is a Union regulatory procedure used when pharmacovigilance data concerning one or more centrally authorised medicinal products (CAPs) indicate that regulatory action may be required under the pharmacovigilance or supervision provisions of EU medicines legislation.

Its legal basis is Article 20 of Regulation (EC) No 726/2004.

The defining features are therefore twofold:

1. the issue arises from the evaluation of pharmacovigilance data; and
2. the medicinal product or products concerned are authorised through the centralised procedure only.

The procedure should not be understood simply as “an EMA safety referral”. It is a specific legal mechanism with a defined allocation of responsibilities between the European Commission, EMA, PRAC, CHMP and the marketing authorisation holder.

A simplified representation is:

Pharmacovigilance data
        ↓
Member State / Commission assessment
        ↓
European Commission initiates Article 20
        ↓
EMA / PRAC scientific assessment
        ↓
PRAC recommendation
        ↓
CHMP opinion
        ↓
European Commission decision
        ↓
MAH implementation
        ↓
Continuing pharmacovigilance

The actual procedural documents and timing should always be checked for the individual procedure.

2. The Legal Foundation

Article 20 is established by Regulation (EC) No 726/2004.

The procedure belongs to the Union framework for the supervision and pharmacovigilance of centrally authorised medicines.

This legal basis is important because it explains why the procedure differs from the Article 31 pharmacovigilance referral under Directive 2001/83/EC.

Article 20 is tied to the centralised authorisation system established by Regulation (EC) No 726/2004. Article 31, by contrast, is a broader referral mechanism under the Directive and can encompass nationally authorised medicines where its statutory conditions are met.

For a live regulatory question, the current consolidated version of Regulation (EC) No 726/2004 should be consulted. EMA's Article 20 pharmacovigilance questions and answers are operational guidance and expressly state that they should be read together with the applicable EU legislation. citeturn0search0

3. Why Does Article 20 Exist?

The centralised procedure creates a single Union marketing-authorisation framework for the medicines within its scope. Pharmacovigilance therefore also needs a mechanism through which an important safety issue affecting a centrally authorised medicine can be assessed and, where necessary, acted upon at Union level.

Article 20 provides that mechanism.

It prevents a safety concern involving a centrally authorised medicine from being managed as a series of unrelated national regulatory decisions. The scientific assessment is coordinated through the Union pharmacovigilance system, with PRAC performing the principal pharmacovigilance assessment and CHMP subsequently adopting its opinion within the applicable framework.

The European Commission then performs the legally operative decision-making function.

This produces an important regulatory separation:

PRAC assesses the pharmacovigilance issue scientifically; CHMP adopts the relevant scientific opinion; the European Commission adopts the binding Union decision.

That distinction is central to reading an Article 20 procedure correctly.

4. When Does Article 20 Apply?

According to current EMA procedural guidance, an Article 20 pharmacovigilance procedure applies when a procedure is initiated as a result of the evaluation of data relating to pharmacovigilance for medicinal products authorised through the centralised procedure.

More specifically, the procedure is used where a Member State or the European Commission, following evaluation of pharmacovigilance data, considers that one or more measures provided for under the relevant pharmacovigilance or supervision provisions of Directive 2001/83/EC should be applied to centrally authorised medicinal products. citeturn0search0

This formulation contains an important logical sequence:

Pharmacovigilance information
        ↓
Evaluation of that information
        ↓
Regulatory concern
        ↓
Potential statutory measure
        ↓
Article 20 procedure

The existence of a safety signal alone should therefore not be equated automatically with an Article 20 procedure.

Routine pharmacovigilance contains many safety assessments that do not become Article 20 procedures. Article 20 represents a formal Union regulatory pathway when the applicable legal conditions for that pathway are met.

5. Which Medicines Can Be Included?

The scope of an Article 20 pharmacovigilance procedure is determined by the products affected by the safety concern and their authorisation status.

The current EMA guidance states that an Article 20 pharmacovigilance procedure is initiated where only centrally authorised medicinal products are concerned.

The scope can involve:

• one centrally authorised medicinal product;
• a range of medicinal products containing the same active substance; or
• medicinal products belonging to a therapeutic class where the relevant products are centrally authorised. citeturn0search0

This matters because authorisation status helps determine the correct legal pathway.

If a safety concern extends beyond centrally authorised products and includes nationally authorised products, the appropriate legal mechanism may instead be an Article 31 pharmacovigilance referral or an Article 107i urgent Union procedure, depending on the circumstances. EMA's current Article 20 guidance explicitly directs readers to those procedures when the affected range includes both CAPs and nationally authorised medicines. citeturn0search0

Thus, when assessing a possible Article 20 procedure, one of the first regulatory questions is:

Which marketing authorisations are actually within the safety concern?

6. Article 20 Is Not the Same as Article 31

The two procedures are related but should not be treated as interchangeable.

The difference is not merely administrative.

The legal basis determines who can initiate the procedure, which products fall within its scope, how the assessment is structured and how the resulting decision is implemented.

A safety concern should therefore be classified from the formal legal and procedural facts, not simply from its medical subject matter.

7. Article 20 Is Not the Same as Article 107i

Article 107i provides the urgent Union procedure for certain pharmacovigilance situations requiring urgent Union-level action.

Article 20 is different.

A useful conceptual distinction is:

Centrally authorised medicines only
        +
Pharmacovigilance regulatory concern
        ↓
Article 20

Urgent Union safety situation meeting
Article 107i statutory conditions
        ↓
Article 107i

The existence of a serious safety issue does not by itself determine which procedure applies.

The statutory trigger, urgency, products affected and applicable legal framework must be established.

This is particularly important because Article 107i can encompass a broader product population where both centrally and nationally authorised medicines are affected, whereas Article 20 is confined to the centrally authorised scope described above. citeturn0search0

8. Who Can Initiate an Article 20 Pharmacovigilance Procedure?

A particularly important feature of Article 20 is that the European Commission initiates the formal procedure.

The current EMA questions and answers state explicitly that an MAH cannot trigger an Article 20 pharmacovigilance procedure.

The European Commission refers the safety matter to EMA and requests an opinion from CHMP based on a PRAC recommendation. The notification identifies the safety concern, explains the issue and identifies the need for regulatory action to be considered. citeturn0search0

This creates an important distinction between:

• the origin of the safety information;
• the scientific evaluation of the information;
• the formal initiation of the Article 20 procedure; and
• the MAH's participation in the assessment.

These should not be collapsed into one event.

9. Can a Member State Act Before the Article 20 Decision?

A centrally authorised medicine is subject to a Union marketing authorisation, but EU legislation provides a mechanism for urgent national protective action in circumstances where immediate action is essential to protect public health.

Current EMA Article 20 guidance explains that a Member State may, on its own initiative or at the Commission's request, suspend use of a centrally authorised medicinal product in its territory pending a definitive decision. Where a Member State takes such action on its own initiative, it must inform the Commission and EMA within the applicable legal timeframe; the Agency then informs the other Member States and the Commission initiates an Article 20 procedure if one is not already ongoing. citeturn0search0

This mechanism illustrates an important principle of the EU regulatory system:

A centralised authorisation does not prevent immediate protective action where the legislation provides a specific mechanism for urgent public-health protection.

Such national action should not be confused with the final Union decision resulting from the Article 20 procedure.

10. The Formal Notification Starts a Defined Regulatory Process

Once the European Commission formally refers the matter to EMA, the Article 20 procedure becomes a defined regulatory process.

The notification should be treated as the authoritative starting document for reconstructing the procedure.

For regulatory professionals, the initial record should establish:

• the legal basis;
• the procedure number;
• the medicinal product or products concerned;
• the active substance or substances where relevant;
• the safety concern;
• the reason regulatory action is being considered;
• the scope of the procedure;
• the affected MAHs; and
• the procedural timetable and instructions applicable to the assessment.

The public announcement and procedure documentation are important sources, but the governing legislation and formal regulatory documents remain the primary references for determining legal effect.

11. PRAC and CHMP Have Different Functions

The Article 20 pharmacovigilance procedure provides a particularly clear example of the division between pharmacovigilance expertise and broader medicinal-product scientific assessment.

PRAC

PRAC performs the principal pharmacovigilance assessment.

Its work includes evaluating the safety evidence and developing the pharmacovigilance recommendation that forms the basis for the subsequent CHMP process.

CHMP

CHMP considers the PRAC recommendation within the centralised regulatory framework and adopts the relevant opinion.

European Commission

The European Commission subsequently conducts the applicable decision-making process leading to the legally binding Union decision.

The sequence can therefore be represented as:

Safety concern
      ↓
Article 20 initiated by European Commission
      ↓
PRAC assessment
      ↓
PRAC recommendation
      ↓
CHMP consideration and opinion
      ↓
European Commission decision

The precise documents generated at each stage should be read separately. A PRAC recommendation, a CHMP opinion and a Commission decision are not interchangeable documents.

12. The MAH's Role Begins With Evidence, Not Advocacy

Once included in an Article 20 procedure, the MAH becomes an important source of evidence for the assessment.

The company's task is not simply to defend the existing label.

It should provide the evidence necessary for the scientific assessment of the concern, including relevant information supporting and challenging the proposed interpretation.

A strong response should allow the assessors to understand:

• what is known;
• what is uncertain;
• what the individual cases show;
• what epidemiological or clinical evidence contributes;
• whether the signal is consistent across data sources;
• what alternative explanations exist;
• how the concern affects the benefit-risk balance; and
• what regulatory measures may be proportionate.

This is especially important in pharmacovigilance because the existence of reports does not itself establish causality, incidence or clinical significance.

The MAH should therefore distinguish observations from conclusions and conclusions from regulatory recommendations.

13. The Article 20 Procedure as a Lifecycle Safety Mechanism

An Article 20 procedure should not be viewed as an isolated regulatory event.

It sits within the broader lifecycle of the centrally authorised medicine:

Authorisation
      ↓
Routine pharmacovigilance
      ↓
New safety information
      ↓
Signal detection / evaluation
      ↓
Regulatory concern
      ↓
Article 20 procedure, where applicable
      ↓
Regulatory action
      ↓
Updated product information / RMP / PV measures
      ↓
Continuing monitoring

The outcome can therefore establish a new regulatory baseline for future pharmacovigilance.

A safety issue identified through the procedure may subsequently influence signal management, risk-management activities, aggregate safety assessments and further regulatory procedures.

For a QPPV, this lifecycle perspective is essential. The Article 20 procedure is not merely an external regulatory process; it can change the operating assumptions of the company's pharmacovigilance system.

14. Why Article 20 Matters to a QPPV

The QPPV should be able to understand an Article 20 procedure at three levels.

Legal level

What is the legal basis, why does Article 20 apply, and what is the legally operative outcome?

Scientific level

What evidence led to the safety concern, what did PRAC conclude, what uncertainty remains, and how did the benefit-risk assessment change?

System level

What does the outcome require the MAH to change in its pharmacovigilance system, RMP, product information, risk-minimisation measures and ongoing monitoring?

The QPPV does not need to perform every regulatory task personally. The responsibility is to maintain effective oversight of the pharmacovigilance system and ensure that the safety consequences of the regulatory decision are appropriately incorporated.

The next sections of this article will therefore examine the actual Article 20 workflow in greater depth, including the MAH evidence package, PRAC assessment, questions and responses, oral explanations, CHMP opinion, Commission decision and implementation.

15. Preparing the MAH Evidence Package

Once the Article 20 procedure has been formally initiated, the MAH should move quickly from routine signal-management activity to a controlled regulatory evidence programme.

The first task is to define the question precisely. The company should identify the safety concern as described in the referral notification and distinguish that question from broader concerns that may be scientifically interesting but are outside the formal scope.

A useful evidence map is:

Formal regulatory question
        ↓
Known evidence
        ↓
New evidence required
        ↓
Analysis
        ↓
Interpretation
        ↓
Uncertainty
        ↓
Benefit-risk consequence
        ↓
Regulatory position

The purpose is not to produce the largest possible dossier. It is to produce a coherent scientific record from which the assessors can understand the evidence and the company's interpretation.

16. Individual Case Evidence

For a pharmacovigilance procedure, individual case safety reports can be an important part of the evidence base.

The MAH should ensure that relevant cases have undergone appropriate medical review and that important missing information has been pursued where follow-up is appropriate.

The analysis should consider the quality and limitations of the cases rather than simply counting reports.

Relevant considerations can include:

• temporal relationship;
• alternative causes;
• dechallenge and rechallenge where available;
• clinical course;
• concomitant medicines;
• underlying disease;
• exposure information;
• relevant risk factors; and
• consistency across cases.

A case series may support a safety signal without establishing incidence or causality on its own.

This distinction is fundamental when a company is responding to a formal regulatory safety assessment.

17. Cumulative Evidence and Signal History

PRAC's assessment should be informed by the cumulative safety history rather than by a single recent case or a single analysis.

The MAH should therefore be able to reconstruct:

• when the signal or concern was first identified;
• previous internal assessments;
• previous regulatory discussions where relevant;
• changes in reporting patterns;
• previous risk-minimisation measures;
• relevant aggregate-report conclusions; and
• important new evidence since earlier assessments.

The historical record is particularly important when the company has previously concluded that the evidence did not support a regulatory action.

A previous conclusion is not necessarily invalid simply because a later assessment reaches a different conclusion. The evidence base may have changed.

The company should instead explain what has changed and why the current interpretation follows from the current evidence.

18. Exposure and Denominators

Safety-report counts can be difficult to interpret without information about exposure.

Where appropriate data are available, the MAH should provide a clear description of the exposed population and the limitations of the exposure estimate.

A spontaneous-reporting database generally does not provide a reliable denominator for calculating incidence merely by dividing reports by an estimate of exposure.

Exposure estimates may be affected by:

• incomplete sales information;
• differences between units sold and patients treated;
• treatment duration;
• dose;
• adherence;
• indications;
• geographic differences; and
• changes in utilisation over time.

The appropriate denominator depends on the scientific question and available data.

False precision should be avoided. A well-qualified exposure estimate is more informative than an apparently exact incidence figure based on unsupported assumptions.

19. Epidemiological and Clinical Evidence

Where epidemiological studies are available, the MAH should integrate them with the spontaneous-reporting and clinical evidence rather than treating each evidence stream independently.

The assessment should consider the design of the study, population, exposure definition, outcome definition, comparator, confounding, bias and statistical uncertainty.

A statistically significant association is not automatically proof of causality.

Conversely, absence of statistical significance does not necessarily demonstrate absence of risk, particularly when a study has limited power or substantial uncertainty.

The regulatory question is therefore broader than whether a p-value crosses a threshold.

The relevant question is what the totality of evidence supports regarding the existence, magnitude, seriousness and manageability of the risk.

20. Benefit-Risk Assessment in an Article 20 Procedure

The purpose of the procedure is not to determine whether the medicine has any risk. Medicines can have risks and still have favourable benefit-risk balances.

The relevant assessment is whether the balance remains favourable under the authorised or proposed conditions of use.

The company should therefore consider:

• the clinical benefits;
• the seriousness and frequency of the suspected risk;
• affected populations;
• risk factors;
• uncertainty;
• available alternatives;
• reversibility or preventability of the risk;
• existing risk-minimisation measures; and
• possible additional measures.

The assessment should remain proportional to the evidence.

Where the MAH recommends no regulatory change, it should explain why the evidence does not justify a change and what ongoing monitoring is appropriate.

Where the MAH supports regulatory action, it should explain why the proposed action addresses the risk and why it is proportionate.

21. PRAC Rapporteurs and Assessment

Within the Article 20 process, PRAC organises the scientific assessment according to its established procedures.

Rapporteurs prepare the scientific assessment for consideration by the committee, supported by the Agency and the relevant experts.

The MAH should therefore understand that its submission is entering a structured committee assessment rather than being evaluated by a single regulator acting independently.

The assessment may involve:

• review of the submitted evidence;
• analysis of the company's arguments;
• additional regulatory questions;
• consideration of external evidence;
• discussion among PRAC members and experts; and
• development of a recommendation.

The company should not assume that the absence of a question means that every aspect of its position has been accepted.

The formal recommendation and supporting assessment documents are the appropriate sources for understanding the committee's conclusions.

22. Questions and Answers During the Procedure

Questions from PRAC or its rapporteurs should be handled through a controlled question-management process.

For each question, the MAH should identify:

1. the exact regulatory question;
2. the scientific owner;
3. the data required;
4. the analytical method;
5. the response;
6. the limitations;
7. internal reviewers; and
8. final approval before submission.

The response should begin by answering the question directly.

Additional background should then be used to explain the answer where necessary.

This structure is especially valuable when questions are complex. A long response that does not make its conclusion easy to locate can make a scientifically strong dossier unnecessarily difficult to assess.

23. When the MAH Disagrees With PRAC's Emerging Interpretation

Scientific disagreement is possible during an Article 20 procedure.

The MAH should express disagreement by identifying the precise point of difference and the evidence supporting its interpretation.

A strong response should:

• identify the conclusion with which the MAH disagrees;
• describe the relevant evidence;
• identify methodological or interpretive issues;
• acknowledge evidence supporting the alternative interpretation;
• explain why the MAH considers its interpretation better supported; and
• state the regulatory consequence of the company's position.

The purpose is not to win an argument. It is to ensure that the committee has a complete understanding of the scientific basis for the company's position.

24. Oral Explanations

Where the applicable Article 20 procedure provides an opportunity for an oral explanation, the MAH should treat it as part of the formal regulatory assessment rather than as a commercial presentation.

The oral explanation is most useful when it focuses on issues that remain material after review of the written evidence.

The company should be prepared to explain:

• its strongest evidence;
• important limitations;
• unresolved uncertainty;
• alternative interpretations; and
• the regulatory action it considers proportionate.

The presentation should remain consistent with the written submission.

If new evidence becomes relevant, its procedural status should be made clear rather than presenting it as though it were part of the original submission.

25. PRAC Recommendation

Following its assessment, PRAC adopts its recommendation within the Article 20 procedure.

The recommendation should be read as a complete regulatory document rather than reduced to a headline such as “label update” or “restriction”.

The recommendation may address the scientific grounds, benefit-risk balance, product-information changes, risk-minimisation measures, additional pharmacovigilance activities or other regulatory measures relevant to the case.

For the MAH, this is a critical transition point.

The company should compare the recommendation with its submitted position and identify every material difference.

Those differences may determine what the company needs to prepare for the subsequent CHMP and Commission stages.

26. CHMP Opinion

After PRAC has adopted its recommendation, the matter proceeds through the applicable centralised framework to CHMP.

CHMP considers the recommendation and adopts its opinion.

The opinion is a scientific regulatory document, but it is not the same as the European Commission's legally binding decision.

The distinction can be represented as:

PRAC recommendation
        ↓
CHMP consideration
        ↓
CHMP opinion
        ↓
European Commission
        ↓
Binding Union decision

The final legal effect therefore should be determined from the Commission decision and applicable legislation, not inferred solely from a PRAC recommendation.

27. The European Commission Decision

The European Commission adopts the legally binding decision under the applicable Union framework.

The decision translates the scientific assessment into a legally operative regulatory outcome.

Depending on the case, the outcome can include changes to the conditions of use, product information, risk-management measures or other regulatory action available under the applicable legislation.

The MAH should distinguish carefully between:

• the evidence submitted by the company;
• PRAC's recommendation;
• the CHMP opinion; and
• the Commission decision.

These documents form a regulatory chain, but they have different legal and scientific functions.

28. Implementing the Outcome

Once the Commission decision is adopted, the MAH must implement the resulting requirements within the applicable regulatory framework.

Potential consequences include:

• revised SmPC;
• revised Package Leaflet;
• revised labelling;
• RMP changes;
• additional risk-minimisation measures;
• additional pharmacovigilance activities; and
• other regulatory actions specified by the decision.

The company should establish a controlled implementation plan linked directly to the final decision.

Internal implementation actions should be distinguished from legally mandated actions.

For example, a company may create internal training or governance controls to support implementation. Those controls are useful but should not automatically be described as statutory requirements.

29. Updating the Pharmacovigilance System

A significant Article 20 outcome can change the assumptions underlying the MAH's pharmacovigilance system.

The company should assess whether the new safety conclusion affects:

• signal detection and monitoring;
• case follow-up;
• medical review;
• aggregate safety reporting;
• RMP activities;
• risk-minimisation effectiveness evaluation;
• safety specifications; or
• other relevant PV processes.

The exact consequences depend on the final regulatory outcome.

The important principle is that a product-information change is not necessarily the end of the pharmacovigilance work.

The regulatory conclusion becomes part of the continuing safety lifecycle.

30. QPPV Oversight After the Decision

The QPPV should verify that the pharmacovigilance consequences of the decision have been addressed.

A practical review can ask:

The QPPV should not be expected to perform every implementation task personally. The responsibility is effective oversight of the pharmacovigilance system.

31. What an Article 20 Procedure Can Teach the MAH

An Article 20 procedure can reveal weaknesses that are broader than the immediate safety concern.

For example, the company may discover that:

• safety data are difficult to reconcile across systems;
• exposure information is poorly controlled;
• previous signal assessments are insufficiently traceable;
• different functions hold inconsistent safety interpretations;
• RMP commitments are not adequately linked to safety conclusions; or
• regulatory implementation controls are fragmented.

These findings should be considered as part of the company's continuous improvement system.

A regulatory procedure is therefore not merely an event to be closed. It can provide evidence about the maturity of the pharmacovigilance system itself.

32. Inspection and Audit Perspective

An Article 20 procedure can create a significant inspection trail.

The company should be able to reconstruct:

Safety information
      ↓
Internal signal / concern assessment
      ↓
Regulatory escalation
      ↓
Article 20 notification
      ↓
MAH evidence and responses
      ↓
PRAC recommendation
      ↓
CHMP opinion
      ↓
Commission decision
      ↓
Implementation
      ↓
Continuing monitoring

The exact inspection expectations depend on the inspection scope and applicable requirements.

However, traceability should exist between the evidence available to the company, its regulatory submissions, the final regulatory outcome and the subsequent PV actions.

33. Common Misconceptions

“Article 20 is just an EMA referral.”

It is a specific statutory pharmacovigilance procedure under Regulation (EC) No 726/2004.

“The MAH can request Article 20 directly.”

The MAH can provide information and participate in the assessment, but the current Article 20 PV procedure is formally initiated by the European Commission.

“PRAC makes the final decision.”

PRAC makes the pharmacovigilance recommendation; CHMP adopts its opinion and the European Commission performs the applicable legally operative decision-making.

“Any CAP safety signal becomes Article 20.”

Routine pharmacovigilance generates many signals and assessments that do not become formal Article 20 procedures.

“Article 20 and Article 107i are interchangeable.”

They have different statutory triggers and procedural contexts.

“The Commission decision is just a summary of the PRAC recommendation.”

The documents are related but have distinct roles and legal significance.

“Once the Commission decision is implemented, the QPPV's involvement ends.”

The regulatory outcome can change the continuing pharmacovigilance system and therefore remains relevant to QPPV oversight.

Key Takeaways

1. Article 20 is the specific pharmacovigilance procedure for centrally authorised medicinal products under Regulation (EC) No 726/2004.
2. The European Commission formally initiates the Article 20 pharmacovigilance procedure.
3. The MAH does not initiate Article 20, but it has a substantial role in supplying evidence and responding to the assessment.
4. PRAC performs the principal pharmacovigilance assessment and adopts its recommendation.
5. CHMP considers the PRAC recommendation and adopts its opinion within the centralised framework.
6. The European Commission adopts the legally operative Union decision.
7. Article 20 should not be confused with Article 31 pharmacovigilance referrals or Article 107i urgent Union procedures.
8. Authorisation status is a fundamental determinant of the applicable referral pathway.
9. The MAH should distinguish individual case evidence, epidemiological evidence, exposure estimates, interpretation and regulatory conclusions.
10. A PRAC recommendation, CHMP opinion and Commission decision are separate regulatory documents and should not be treated as interchangeable.
11. Implementation can affect product information, the RMP, risk-minimisation measures and ongoing pharmacovigilance.
12. The QPPV's role is primarily one of effective oversight of the pharmacovigilance consequences rather than personal ownership of every regulatory implementation task.
13. An Article 20 procedure can expose broader weaknesses in evidence governance, signal management, risk management or regulatory implementation.
14. The procedure should be understood as part of the medicine's continuing safety lifecycle, not as an isolated regulatory event.

References

1. European Parliament and Council. Regulation (EC) No 726/2004, as amended. Primary legal basis for the centralised authorisation system and Article 20 pharmacovigilance procedures.
2. European Parliament and Council. Directive 2001/83/EC, as amended. Relevant provisions concerning pharmacovigilance measures and referral mechanisms that interact with the Article 20 framework.
3. European Medicines Agency. Questions and answers: Article 20 pharmacovigilance procedures. Current EMA procedure-specific guidance on scope, initiation, PRAC, CHMP, MAH participation and implementation.
4. European Medicines Agency. Referral procedures for human medicines. Current overview of Union referral mechanisms.
5. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Current information concerning PRAC responsibilities and scientific role.
6. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Current information concerning CHMP's role in the centralised regulatory system.
7. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module I — Pharmacovigilance systems and their quality systems. Current guidance relevant to PV governance and quality.
8. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module V — Risk Management Systems. Current guidance concerning RMPs and risk-minimisation measures.
9. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module IX — Signal Management. Current guidance concerning signal detection, validation, analysis and management.

Primary-document hierarchy

For an active Article 20 procedure, the following practical hierarchy should be applied:

1. current EU legislation;
2. formal European Commission referral notification;
3. procedure-specific EMA documents and timetable;
4. PRAC recommendation and supporting assessment;
5. CHMP opinion and annexes;
6. European Commission decision;
7. applicable implementation documents and current EMA guidance.

Secondary explanations can help with orientation but should not replace the primary documents when determining legal effect or procedural requirements.

Regulatory Note

This article is an educational explanation of Article 20 pharmacovigilance procedures for centrally authorised medicines. It is not legal advice and does not replace Regulation (EC) No 726/2004, Directive 2001/83/EC, current EMA guidance, GVP, the formal referral notification, procedure-specific documents or the European Commission decision applicable to an individual case.

The exact scope, products concerned, procedural timetable, questions, assessment documents, regulatory measures and implementation requirements depend on the individual Article 20 procedure.

The article deliberately distinguishes the roles of the European Commission, EMA, PRAC, CHMP and the MAH. It also distinguishes a PRAC recommendation, a CHMP opinion and the final legally operative Commission decision.

Examples of internal MAH governance and implementation controls are practical models rather than universal statutory requirements. The applicable legislation and procedure-specific regulatory documents take precedence.

EU medicines legislation and regulatory guidance are amended periodically. For a live regulatory assessment, the current consolidated legislation and current EMA/Commission procedural documents should therefore always be checked.